DDInter298 DDInter519
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes , , and ), dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing.[A19566, A19568, A178084, A174244] Dexlansoprazole inhibits the final step in gastric acid production by blocking the (H+, K+)-ATPase enzyme.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Methotrexate
Methotrexate {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Erlotinib
Erlotinib {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Vandetanib
Vandetanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Carboplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexlansoprazole
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Dexlansoprazole
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Erlotinib (Compound) and Erlotinib may lead to a major life threatening interaction when taken with Dexlansoprazole
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Dexlansoprazole
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vandetanib (Compound) and Vandetanib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Carboplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole